How common is residual inflammatory risk?

Circulation Research

Volumn 120, Issue 4, 2017, Pages 617-619

  Ridker, Paul M ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

atherosclerosis; C reactive protein; cholesterol; inflammation; prevention

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; LIPOPROTEIN; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CLINICAL TRIAL (TOPIC); HUMAN; INFLAMMATION; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RESIDUAL CHOLESTEROL RISK; RESIDUAL INFLAMMATORY RISK; REVIEW; RISK; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; HYPERCHOLESTEROLEMIA; IMMUNOLOGY; MULTICENTER STUDY (TOPIC); TRANSLATIONAL RESEARCH;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; BIOMARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPOPROTEINS; MULTICENTER STUDIES AS TOPIC; PROPROTEIN CONVERTASE 9; RISK; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85013276200     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.310527     Document Type: Review

References (15)

1. Pedersen TR, The success story of LDL cholesterol lowering. Circ Res 2016 118 721 731. doi: 10.1161/CIRCRESAHA.115.306297
2. Ridker PM, Mora S, Rose L, JUPITER Trial Study Group Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J 2016 37 1373 1379. doi: 10.1093/eurheartj/ehw046
3. Boekholdt SM, Hovingh GK, Mora S, Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014 64 485 494. doi: 10.1016/j.jacc.2014.02.615
4. Shapiro MD, Fazio S, From lipids to inflammation: new approaches to reducing atherosclerotic risk. Circ Res 2016 118 732 749. doi: 10.1161/CIRCRESAHA.115.306471.
5. Cybulsky MI, Cheong C, Robbins CS, Macrophages and dendritic cells: partners in atherogenesis. Circ Res 2016 118 637 652. doi: 10.1161/CIRCRESAHA.115.306542
6. Ketelhuth DF, Hansson GK, Adaptive response of T and B cells in atherosclerosis. Circ Res 2016 118 668 678. doi: 10.1161/CIRCRESAHA.115.306427
7. Tabas I, Bornfeldt KE, Macrophage Phenotype and Function in Different Stages of Atherosclerosis. Circ Res 2016 118 653 667. doi: 10.1161/CIRCRESAHA.115.306256
8. Ridker PM, Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J 2016 37 1720 1722. doi: 10.1093/eurheartj/ehw024
9. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005 352 20 28. doi: 10.1056/NEJMoa042378
10. Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E, Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 2015 132 1224 1233. doi: 10.1161/CIRCULATIONAHA.115.018381
11. Lu Y, Zhou S, Dreyer RP, Sex differences in inflammatory markers and health status among young adults with acute myocardial infarction: Results from the VIRGO study. Circ Cardiovasc Qual Outcomes 2016. In press
12. Crea F, Liuzzo G, Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine. Eur Heart J 2016 37 2414 2416. doi: 10.1093/eurheartj/ehw207
13. Ridker PM, From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res 2016 118 145 156. doi: 10.1161/CIRCRESAHA.115.306656
14. Sager HB, Heidt T, Hulsmans M, Dutta P, Courties G, Sebas M, Wojtkiewicz GR, Tricot B, Iwamoto Y, Sun Y, Weissleder R, Libby P, Swirski FK, Nahrendorf M, Targeting Interleukin-1β Reduces Leukocyte Production After Acute Myocardial Infarction. Circulation 2015 132 1880 1890. doi: 10.1161/CIRCULATIONAHA.115.016160
15. Swirski FK, Nahrendorf M, Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013 339 161 166. doi: 10.1126/science.1230719